Komori
Presentation materials for financial results6090Human Metabolome Technologies,Inc.Information and Communications, Services and Others

Presentation Materials for the Interim Results for the Fiscal Year Ending June 2026

For the interim period of the fiscal year ending June 2026, revenue decreased 3.7% year on year to ¥659 million and operating profit fell 55.2% to ¥46 million. Profit declined due to sluggish life science research support services, as well as higher capital expenditures and personnel expenses.

Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
-57
¥ millions (year-on-year change in operating income)
Wording
Conditional
How definitive the wording is.

Contents of this document

Presentation materials for financial results2026年6月期 中間期10 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥659 million-3.7%
Operating profit¥46 million-55.2%
Ordinary income¥47 million-50.3%
Net income¥43 million -52.9%interim net income attributable to owners of the parent
Full-year earnings forecast
Net Sales
¥1,600 million
Operating profit
¥300 million
Ordinary income
¥300 million
Profit attributable to owners of the parent
¥260 million
Earnings per share
¥45.68
Dividend per share
¥18
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
設備投資と人件費増による費用増。要因別金額はNot disclosed。
New initiatives
  • バイオものづくり支援サービスの拡大
  • 独自技術とAIによる生産性向上
  • 集中的な研究開発投資
  • キャピタル・アロケーション方針に基づく自己株式取得
Segment results
  • ServiceLife Science research support services (LSS)
    Net Sales
    ¥440 million
    Year on year against the same period last year-16.6%
  • ServiceFunctional materials development support services (FDS)
    Net Sales
    ¥167 million
    Year on year against the same period last year+7.1%
  • ServiceBio-manufacturing support services (BMS)
    Net Sales
    ¥51 million
Medium-term management plan targets
ROEを中長期的に15%以上。2024年6月期〜2026年6月期は成長基盤構築、2026年6月期以降は企業成長。
Financial targets
ROE target中長期的に15%以上
Number of employees
62 Number連結、2025年6月現在
Capital expenditures
5 億円戦略投資資金としてM&A・設備投資などに確保
Annual Dividend
¥18 per share
Payout ratio
40 Approximately %
Acquisition of treasury shares
Total number of shares acquired
250,000 Shares
Total acquisition cost
¥2 100 million maximum
Acquisition period2026年2月13日〜2026年12月31日
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period Covered2026年6月期 中間期
Net Sales¥659 million (YoY -3.7%)
Operating profit¥46 million (YoY -55.2%)
Ordinary income¥47 million (YoY -50.3%)
Net income¥43 million (interim net income attributable to owners of the parent) (YoY -52.9%)
Full-year earnings forecastNet Sales ¥1,600 million / Operating profit ¥300 million / Ordinary income ¥300 million / Profit attributable to owners of the parent ¥260 million / Earnings per share ¥45.68 / Dividend per share ¥18
Segment resultsService Life Science research support services (LSS) / Net Sales ¥440 million / yoy_pct -16.6, Service Functional materials development support services (FDS) / Net Sales ¥167 million / yoy_pct 7.1, Service Bio-manufacturing support services (BMS) / Net Sales ¥51 million / yoy_pct Not disclosed
Breakdown of Factors Affecting the Change設備投資と人件費増による費用増。要因別金額はNot disclosed。
Number of employees62 名（連結、2025年6月現在）
Medium-term management plan targetsROEを中長期的に15%以上。2024年6月期〜2026年6月期は成長基盤構築、2026年6月期以降は企業成長。
Financial targetsROE target 中長期的に15%以上 / Actual results Not disclosed
Annual Dividend¥18 per share
Payout ratio40 Approximately %
Acquisition of treasury sharesTotal number of shares acquired 250,000 Shares / Total acquisition cost ¥2 100 million (maximum) / Acquisition period 2026年2月13日〜2026年12月31日
Capital expenditures5 億円（戦略投資資金としてM&A・設備投資などに確保）
New initiativesバイオものづくり支援サービスの拡大, 独自技術とAIによる生産性向上, 集中的な研究開発投資, キャピタル・アロケーション方針に基づく自己株式取得
Items this document does not state (14)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

ライフサイエンス研究支援サービスでは、製薬企業の大型案件が下期にずれ込み、食品企業の大型案件が今期は端境期で減少し、米国事業も低迷した。利益については、設備投資と人件費の増加による費用増が理由として示されている。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Presentation Materials for the Interim Results for the Fiscal Year Ending June 2026 | Human Metabolome Technologies,Inc. (6090) timely disclosure | Komori